Print

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

https://www.facingourrisk.org/research-clinical-trials/study/107/combination-chemotherapy-with-or-without-atezolizumab-in-treating-patients-with-stage-iii-colon-cancer-and-deficient-dna-mismatch-repair

Clinicaltrials.gov identifier:
NCT02912559 (https://clinicaltrials.gov/show/NCT02912559)


Study Contact Information:

For additional information, please contact: Principal Investigator: Frank A Sinicrope, Alliance for Clinical Trials in Oncology


About the Study

Immunotherapy may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

This phase III trial is for people with stage 3 colon cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment with combination chemotherapy agents alone. This study is focused on patients who have a biomarker known as MSI-High or dMMR, which are commonly seen in people with Lynch syndrome. NOTE: This study is no longer enrolling people. 

What the Study Involves

People will be assigned randomly to one of two groups:

Group 1: Chemotherapy and immunotherapy

Group 2: Chemotherapy only

Both groups of participants will be followed for up to 5 years.

Study Sites

Alaska Arizona California Colorado Connecticut
Delaware DC Florida Georgia Hawaii
Idaho Illinois Indiana Iowa Kansas
Kentucky Louisiana Maine Maryland Massachusetts
Michigan Minnesota Missouri Montana Nevada
New Hampshire New Jersey New Mexico New York North Carolina
North Dakota Ohio Oklahoma Oregon Pennsylvania
Rhode Island South Carolina South Dakota Tennessee Texas
Utah Virginia Washington West Virginia Wisconsin


Alaska 

  Arizona

California

Colorado

Connecticut

Delaware

District of Columbia

Florida

Georgia

Hawaii

Idaho

Illinois

Indiana

Iowa

Kansas

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Minnesota

Missouri

Montana

Nebraska

Nevada

New Hampshire

New Jersey


This Study is Open To:

Men or women age 18 years or older can participate if they:  

This Study is Not Open To:

Patients will be excluded if they:  


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.